

# Ultrasonic-Assisted Synthesis of Benzofuran Appended Oxadiazole Molecules as Tyrosinase Inhibitors: Mechanistic Approach through Enzyme Inhibition, Molecular Docking, Chemoinformatics, ADMET and Drug-Likeness Studies

Ali Irfan <sup>1</sup>, Ameer Fawad Zahoor <sup>1,\*</sup>, Shagufta Kamal <sup>2</sup>, Mubashir Hassan <sup>3</sup>  
and Andrzej Kloczkowski<sup>3,4,\*</sup>

## SUPPLEMENTARY INFORMATION

### Spectral analysis of compounds 5a-5j

#### 2-((5-(5-Bromobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)thio)-N-(2-fluorophenyl)acetamide (5a)






Figure S1. <sup>1</sup>H NMR spectrum of compound 5a




**Figure S2.** <sup>13</sup>C NMR spectrum of compound 5a

**2-((5-(5-Bromobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)thio)-N-(2-chlorophenyl)acetamide (5b)**




**Figure S3.** <sup>1</sup>H NMR spectrum of compound **5b**




**Figure S4.** <sup>13</sup>C NMR spectrum of compound **5b**

**2-((5-(5-Bromobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)thio)-N-(3,4-dichlorophenyl)acetamide (5c)**




**Figure S5.** <sup>1</sup>H NMR spectrum of compound **5c**




**Figure S6.** <sup>13</sup>C NMR spectrum of compound 5c

**2-((5-(5-bromobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)thio)-N-(4-fluorophenyl)acetamide (5d)**




**Figure S7.** <sup>1</sup>H NMR spectrum of compound **5d**




**Figure S8.** <sup>13</sup>C NMR spectrum of compound **5d**



**2-((5-(5-bromobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)thio)-N-(3,4-dimethylphenyl)acetamide (5e)**




**Figure S9.** <sup>1</sup>H NMR spectrum of compound **5e**




**Figure S10.**  $^{13}\text{C}$  NMR spectrum of compound **5e**


**2-((5-(5-Bromobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)thio)-N-(2-methoxyphenyl)acetamide (5f)**



**Figure S11** <sup>1</sup>H NMR spectrum of compound **5f**



**2-((5-(5-Bromobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)thio)-*N*-phenylacetamide (5g)**



**Figure S13.** <sup>1</sup>H NMR spectrum of compound **5g**






Figure S14. <sup>13</sup>C NMR spectrum of compound **5g**

**2-((5-(5-Bromobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)thio)-N-(2,4-dimethylphenyl)acetamide (5h)**




**Figure S15.**  $^1\text{H}$  NMR spectrum of compound **5h**




**Figure S16.**  $^{13}\text{C}$  NMR spectrum of compound **5h**




**2-((5-(5-Bromobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)thio)-N-(2,5-dimethoxyphenyl)acetamide (5i)**




**Figure S17.**  $^1\text{H}$  NMR spectrum of compound **5i**



**Figure S18.**  $^{13}\text{C}$  NMR spectrum of compound **5i**



**Figure S19.** The moderate biologically active oxadiazole based furan derivatives **5e- 5h** as tyrosinase inhibitors



**Figure S20.** The least biologically active oxadiazole based furan derivatives **5i- 5j** as tyrosinase inhibitors